Innovative treatments are needed for those affected by rare conditions, but how do the economics stack up given the huge costs involved? Elisa Piscopiello, ETF Analyst at LGIM, explains how government incentives are helping to finance the development of life-changing medicines.
This podcast is hosted by Harry Brooks, Content Manager.
All data is from Eikon as at 28 February 2023 unless otherwise stated.
For professional investors only. Capital at risk.
